Eisenhower

@RNAiAnalyst Makary is still FDA Commissioner, and he went on live TV and spoke negatively about this program… And now Street assumes they’ll replace Prasad with someone less controversial and that they’ll all change their tune on $QURE? Doubtful

$qure what would be the point of firing Prasad over personal bias against AMT-130 if it did not improve its regulatory prospects? What would be the next step hinting at it? Announcement of another type A meeting?

@SecKennedy Just words, absolutely nothing behind it. Show me one Pharma that incorporated a meaningful headwind in their full year revenue guidance following the MFN agreement

President Trump is merciless against companies that are taking advantage of their power to profiteer on sickness.

@SteveWagsInvest No reason for them to be a follower in this category (not to mention they got out of diabetes years ago). Plenty of good assets out there, however Shibutani will lead Chris to do some moronic deal and their entire stock narrative will flip to obesity

Hearing more M&A activity on $BMY end for metabolic assets. Looks like they’re open to both early & late stage, but not sure they are going to be as aggressive as $ABBV or $NVO Obesity landscape w M&A should be interesting in 26.

@DoodadDoctor Too far along? ITCI got acquired 5 years post launch with an IP runway into the early/mid 2030s… I think BMRN is a better example of a company that is too far along to be acquired, but ASND is essentially 1 years old with a ton of revenue and EBIT potential ahead…

TransCon CNP is all but guaranteed to be approved on 2/28. $ASND trajectory to achieve profitability and grow is too clear now that it will not be a massive gainer for investors, but none-the-less, a great growing company that is likely TOO far along now to be acquired and can achieve success on their own, but still one of the many ways they can “win.”

$UCB - Mgmt signaling to the Street to “stop taking numbers up” with this guide today… Bim’ decelerating big time (Rx’s not even growing QoQ), rest of the biz not exciting, galvo’ in another dose-finding Phase IIa (this isn’t launching til 2032), donza’ not moving forward…

@TTRAmyloid You’re seeing Vyvgart get used 85% of the time behind IVIg (the only approved therapy in CIDP). Isn’t that the same logic?

@specwiz It’s too expensive. You can achieve the same result with rituximab.

$argx is the next $alny. There’s no way they can grow into their market cap

@TTRAmyloid So Uplizna dead in the water?

$ALKS - Pops is OUT! A true Pharma veteran is stepping down as CEO after 30+ years. How often do you see a CEO step down right before the company’s biggest clinical, regulatory and commercial card flips in almost a decade (or arguably ever)? Good luck, Blair. You’ll need it…

As a long time $JAZZ bear, I couldn’t think of a better time to be long this stock

BD is sensible given uncertainties in the oxybate market - some out there are convinced oxybate and OX2s are going to be used in combination - though it behooves the board to de-risk future revenue growth in the event the market moves towards OX2 monotherapy

And just like that, $JAZZ is back… A 10%+ move in the stock today crushed shorts hoping for a weak guide (re: oxybate pressure on volume & price), and that overhang is now behind us. Management heavily emphasized BD in rare disease on the call - let’s see that card flip over…

Not to mention zani’ couldn’t be launching at a better time… In the event you get meaningful oxybate erosion - zani curbs it with the GEA launch. In the event you don’t, BD to further fuel revenue growth… We’re looking at either healthy revenue growth or accelerated growth...

All of this being said, the board has demonstrated sheer incompetence on capital allocation in recent years - $CTLT being a prime example - and this new CEO is beyond over his head. Can we trust they’d do a smart deal? I think that’s hard to feel totally confident in…

$ARGX, while rare disease, feels out of the NVO wheelhouse, with $INSM being completely out of bounds… They ideally need the type of transaction that $MRK found in $XLRN, though those are few are far between. $ASND makes total sense, but isn’t enough to fill the entire hole

While it’s been years since we’ve seen transformational mega deals in LC Pharma (being they rarely demonstrate success), a very desperate $NVO is likely in pursuit of the next mega deal amid the looming sema’ cliff and lack of revenue diversification - $ALNY the best pick?

and $JAZZ beginning to break free from the oxybate overhang as revenue diversification and M&A continues

Enthusiasm to get behind the mid-cap value traps in biopharma - namely $BMRN, $NBIX, and $JAZZ - is building. None of these without decent controversy, but can this basket of cheap names actually begin to work in this all-forgiving tape? Feels like it…

$BMRN hardly moves these days on competitive pressures and underwhelming guidance for one of their main value drivers, $NBIX trading at floor value with management incompetence driving the share underperformance despite decent growth ahead

@DwightS2025 They announced it a month ago… Isn’t this more of an opportunistic buy back?

$ASND one observation for astute followers: company has not initiated Buyback yet and remains in blackout window. Why? It makes you wonder on recent M&A spec..only thing that would black them out now post EPS. Knowing final label not enough imo. Top M&A 🎯 but who knows!